Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of AMG 757 in Relapsed/Refractory Small Cell Lung Cancer After Two or More Prior Lines of Treatment
2021-002566-40Phase 2Active
- Sponsor
- Amgen
- Start
- Aug 2021
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, single-arm trial of tarlatamab in small cell lung cancer (SCLC), sponsored by Amgen. Primary endpoint: Anti-tumor activity per RECIST 1.1 (BICR). Started Aug 2021; status: active.
02
Drugs
tarlatamab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on 2021-002566-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-002566-40.